Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34 th annual meeting of the Associated Professional Sleep Societies (APSS) from August 28-30
DUBLIN, Aug. 27, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34th annual meeting of the Associated Professional Sleep Societies (APSS) from August 28-30. The presentations will debut data across Jazz’s neuroscience therapeutic area, featuring important new insights into the company’s ongoing sleep medicine research. “At Jazz, we understand that sleep disorders can impact everyday life, which is why we are focused on identifying and developing innovative therapies for people with serious sleep disorders,” said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development of Jazz Pharmaceuticals. “Our goal is to think more holistically about patients’ health so they can live fuller lives and our purpose is to innovate to transform the lives of patients. We are proud to present research at SLEEP on our meaningful therapeutic options for these patients with lifelong, chronic sleep disorders.” Highlights from Jazz at Virtual SLEEP 2020 will include the following presentations on Xywav™ (calcium, magnisium, potassium and sodium oxybate) oral solution (JZP-258), a lower sodium oxybate (LXB) indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy:
The company will also feature two poster presentations on the effects of Sunosi® (solriamfetol) on driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy. The Virtual SLEEP 2020 presentations and exhibit hall are available 24 hours a day for registered attendees from August 28-30 at www.sleepmeeting.org. A full list of Jazz-supported poster presentations are below: Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution (JZP-258) Poster Presentations
Xyrem® (sodium oxybate) oral solution Poster Presentation
Sunosi® (solriamfetol) Poster Presentations
About Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution Important Safety Information WARNING: Taking XYWAV with other central nervous system (CNS) depressants such as medicines used to make you or your child fall asleep, including opioid analgesics, benzodiazepines, sedating antidepressants, antipsychotics, sedating anti-epileptic medicines, general anesthetics, muscle relaxants, alcohol, or street drugs, may cause serious medical problems, including trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), fainting (syncope), and death. The active ingredient of XYWAV is a form of gamma hydroxybutyrate (GHB). Abuse or misuse of illegal GHB alone or with other drugs that cause changes in alertness (or consciousness) has caused serious side effects. These effects include seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma, and death. Call your doctor right away if you or your child has any of these serious side effects. Because of these risks, you have to go through the XYWAV and XYREM REMS Program to have your or your child’s prescription for XYWAV filled. Do not take XYWAV if you take or your child takes other sleep medicines or sedatives (medicines that cause sleepiness), drinks alcohol, or has a rare problem called succinic semialdehyde dehydrogenase deficiency. Keep XYWAV in a safe place to prevent abuse and misuse. Selling or giving away XYWAV may harm others, and is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Anyone who takes XYWAV should not do anything that requires them to be fully awake or is dangerous, including driving a car, using heavy machinery, or flying an airplane, for at least 6 hours after taking XYWAV. Those activities should not be done until you know how XYWAV affects you or your child. XYWAV can cause serious side effects, including the following:
The most common side effects of XYWAV in adults include headache, nausea, dizziness, decreased appetite, parasomnia (a sleep disorder that can include abnormal dreams, abnormal rapid eye movement (REM) sleep, sleep paralysis, sleep talking, sleep terror, sleep-related eating disorder, sleep walking, and other abnormal sleep-related events), diarrhea, excessive sweating (hyperhidrosis), anxiety and vomiting. The most common side effects of XYWAV in children include bedwetting, nausea, headache, vomiting, weight decrease, decreased appetite, and dizziness. XYWAV can cause physical dependence and craving for the medicine when it is not taken as directed. These are not all the possible side effects of XYWAV. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please find full prescribing information here: https://pp.jazzpharma.com/pi/xywav.en.USPI.pdf About Sunosi® (solriamfetol) Important Safety Information for Sunosi SUNOSI (solriamfetol) is available in 75 mg and 150 mg tablets and is a federally controlled substance (C-IV) because it contains solriamfetol that can be a target for people who abuse prescription medicines or street drugs. Keep SUNOSI in a safe place to protect it from theft. Never give or sell your SUNOSI to anyone else, because it may cause death or harm them and it is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Before taking SUNOSI, tell your doctor about all of your medical conditions, including if you:
What are the possible side effects of SUNOSI? SUNOSI may cause serious side effects, including:
The most common side effects of SUNOSI include:
These are not all the possible side effects of SUNOSI. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please find full prescribing information here: https://pp.jazzpharma.com/pi/sunosi.en.USPI.pdf About Xyrem® Important Safety Information for Xyrem WARNING: Taking XYREM with other CNS depressants such as medicines used to make you or your child fall asleep, including opioid analgesics, benzodiazepines, sedating antidepressants, antipsychotics, sedating anti-epileptic medicines, general anesthetics, muscle relaxants, alcohol, or street drugs, may cause serious medical problems, including trouble breathing (respiratory depression), low blood pressure (hypotension), changes in alertness (drowsiness), dizziness (syncope), and death. XYREM is a form of gamma hydroxybutyrate (GHB). Abuse or misuse of illegal GHB alone or with other drugs that cause changes in alertness (or consciousness) has caused serious side effects. These effects include seizures, trouble breathing (respiratory depression), changes in alertness (drowsiness), coma, and death. Because of these risks, you have to go through the XYREM REMS Program to have your or your child’s prescription for XYREM filled. Do not take XYREM if you take or your child takes other sleep medicines or sedatives (medicines that cause sleepiness), drink alcohol, or have a rare problem called succinic semialdehyde dehydrogenase deficiency. Keep XYREM in a safe place to prevent abuse and misuse. Selling or giving away XYREM may harm others and is against the law. Tell your doctor if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Anyone who takes XYREM should not do anything that requires them to be fully awake or is dangerous, including driving a car, using heavy machinery, or flying an airplane, for at least 6 hours after taking XYREM. Those activities should not be done until you know how XYREM affects you or your child. XYREM can cause serious side effects, including the following:
Tell your doctor if you are or your child is on a salt-restricted diet or if you have or your child has high blood pressure, heart failure, or kidney problems. XYREM contains a lot of sodium (salt) and may not be right for you or your child. The most common side effects of XYREM include nausea, sleepiness, dizziness, vomiting, bedwetting, and tremor (in adults). In pediatric patients, headache, decreased appetite, and weight decrease were also common. Your side effects may increase when you take higher doses of XYREM. XYREM can cause physical dependence and craving for the medicine when it is not taken as directed. These are not all the possible side effects of XYREM. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. Please find full prescribing information here: http://pp.jazzpharma.com/pi/xyrem.en.USPI.pdf About Jazz Pharmaceuticals Media Contact: Investor Contact: References:
View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-new-data-on-xywav-calcium-magnesium-potassium-and-sodium-oxybates-oral-solution-and-sunosi-solriamfetol-at-virtual-sleep-2020-301119658.html SOURCE Jazz Pharmaceuticals plc | |||||||||||||||||||||||||||||||||||||||||
Company Codes: NASDAQ-NMS:JAZZ |